Diagnostic tests and prognostic indicators

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Manasanch EE et al. Leuk Lymphoma. 2014 Sep 27:1-24. [Epub ahead of print]. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously…

Details

Related conditions

Finger amyloidosis in a patient with myeloma. Tan J et al. Intern Med. 2014;53(18):2175-6. Epub 2014 Sep 15. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Rosado FG et al. Mod Pathol. 2014 Sep 12. doi: 10.1038/modpathol.2014.117. [Epub ahead of print]. Systemic amyloidosis causing intestinal hemorrhage and…

Details

Emerging treatments

Phase I Trial of Bortezomib and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Holkova B et al. Clin Cancer Res. 2014 Sep 23. pii: clincanres.0805.2014. [Epub ahead of print]. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. He X et al.…

Details

Biology and genetics

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche. Gaudichon J et al. PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Borsi E et al. Exp Cell Res. 2014 Sep 25. pii: S0014-4827(14)00423-6. doi: 10.1016/j.yexcr.2014.09.018.…

Details

Supportive care

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients. Stadtmauer EA et al. Blood. 2014 Sep 18. pii: blood-2014-04-573048. [Epub ahead of print]. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of…

Details

General

Harnessing the immune system for cancer therapy. Smith EL et al. Curr Opin Oncol. 2014 Sep 23. [Epub ahead of print]. CCN1: a sticky issue in myeloma. Roodman GD. Blood. 2014 Sep 25;124(13):2006-8. doi: 10.1182/blood-2014-08-592303. Appraising Myc involvement in high risk myeloma. Kastritis E et al. Leuk Lymphoma. 2014 Sep 26:1-5. [Epub ahead of print].…

Details

Complications of myeloma and its treatments

Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…

Details

Current treatments

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…

Details

Related conditions

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…

Details

General

Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Hultcrantz M et al. Cancer Med. 2014 Aug 26. doi: 10.1002/cam4.316. [Epub ahead of print]. Bortezomib in multiple myeloma: systematic review and clinical considerations. Kouroukis TC et al. Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Novel Agents In Cns Myeloma Treatment.…

Details